# PhillipCapital

# Hengan (01044.HK)

1H2022 sales growth above market expectation, gross margin is expected to remain under pressure China | Consumer

# **Company Profile**

Hengan founded in 1985, is a famous manufacturer of household paper and maternal & child hygiene products. The market shares of the three leading products, namely women's sanitary napkins, baby diapers, and household tissues, is among the best in the domestic market.

# 1H2022 sales bucked the trend and achieved growth of over 10%

For the six months ended 30 June 2022 (1H2022), Hengan's revenue increased by about 12.3% to RMB11,200.021mn, above market expectation. During the period, operating profit fell about 25.8% to RMB1885.753mn (1H2021: RMB2540.583mn). Although the Hengan's sales bucked the trend and achieved growth of over 10%, the striking depreciation of the RMB against the US dollar and HK\$ during the period resulted in a significant foreign exchange loss in the Hengan's operations (RMB367.797mn). Therefore, profit attributable to shareholders was RMB1,276.191mn (1H2021: RMB1,860.292mn), representing a decrease of 31.4% YoY. If deducting the operating foreign exchange loss, profit attributable to shareholders decreased by 10.9% YoY instead. Basic EPS was RMB1.098 (1H2021: RMB1.574), with an interim dividend decreased by 30% YoY to RMB0.70 per share (1H2021: RMB1.00).

During the period under review, rising raw material prices and operating costs have brought enormous pressure to the industry, which accelerated market consolidation of eliminating the weak and retaining the strong. The price of wood pulp, the main raw material of tissue paper, remained high during the period due to geopolitical upheavals, the epidemic and inflation. Overall gross profit slightly increased by 0.3% to RMB3,942.191mn (1H2021: RMB3,930.671mn), however, the overall gross profit margin dropped to 35.2% (1H2021: 39.4%).

By business segment, the sales of sanitary napkin business grew 3.3% to RMB3128.524mn (1H2021: RMB3029.97mn), accounting for around 27.9% (1H2021: 30.4%) of the Hengan's total revenue. However, the surge in petroleum and commodity prices has led to a price hike in petrochemical raw materials used in sanitary napkins, resulting in a YoY decrease of 4.7 percentage points in the gross profit margin of the sanitary napkin business to 65.3% (1H2021: 70.0%).

Although the coronavirus epidemic broke out in many regions, with the re-emergence of the epidemic, the national health awareness has further improved, and the demand for tissue paper continued to be strong. Meanwhile, as small and medium-sized tissue paper companies cannot withstand the soaring costs which affect their business development, Hengan has gained more market shares leveraging its strong capital strength and nationwide sales network. Thus, the revenue of Hengan's tissue paper business increased substantially by close to 25.0% to RMB5,842.612mn (1H2021: RMB4,696.522mn), accounting for 52.2% of the overall revenue (1H2021: 47.1%). However, affected by the sharp surge in wood pulp prices due to the tight supply of wood pulp and logistical disruption. High wood pulp prices exerted enormous pressure on the Hengan's gross profit in 1H2022, and the gross profit margin dropped to approximately 23.1% (1H2021: 29.2%).

15 November 2022

# **Accumulate**

CMP HKD32.90 (Closing price as of 10 November) Target HKD 37.90 (+15.2%)


#### **COMPANY DATA**

| O/S SHARES (MN):     | 1162.120917 |
|----------------------|-------------|
| MARKET CAP (HKD MN): | 38233.8     |
| 52 - WK HI/LO (HKD): | 41.73/30.10 |

# **SHARE HOLDING PATTERN, %**

| Mr. Hui Lin Chit | 23.14% |
|------------------|--------|
| Mr. Sze Man Bok  | 20.57% |

#### PRICE VS. HSI



Source: Phillip Securities (HK) Research

# **KEY FINANCIALS**

| RMB mn            | FY21   | FY22   | FY23E  | FY24E  |
|-------------------|--------|--------|--------|--------|
| Revenue           | 22,374 | 20,790 | 22,913 | 23,747 |
| Net profit        | 4,595  | 3,274  | 3,286  | 3,849  |
| Reported EPS      | 3.86   | 2.79   | 2.82   | 3.33   |
| P/E ratio, x      | 7.1    | 9.6    | 10.7   | 9.1    |
| Dividend Yield, % | 8.8%   | 6.3%   | 5.9%   | 6.9%   |

Source: Company reports, Phillip Securities Est.

# Sr. Research Analyst

Eric Li (+852 2277 6516) erichyli@phillip.com.hk The sales of the Hengan's disposable diaper business rebounded, and the revenue increased by 2.2% to RMB633.513mn (1H2021: RMB619.668mn), accounting for 5.7% of the overall revenue (1H2021: 6.2%). As significant rise in the cost of sales caused by the price increase in petrochemical raw materials for disposable diapers during the period, but the increase in the proportion of sales of higher-margin "Q • MO" products offset part of the impact of rising costs on the overall business profitability. Thus, the gross profit margin of the disposable diapers business only dropped slightly to about 35.3% (1H2021: 36.2%).

Regarding other income and household products, the Hengan's revenue decreased by 2.0% YoY to RMB1595.372mn (1H2021: RMB1627.754mn), accounting for 14.2% of the overall revenue (1H2021: 16.3%). In which, medical products do not account for a significant portion of the overall revenue, but medical products have higher profit margin, which effectively increased the overall gross profit margin of other businesses by 7.2 percentage points to 20.4% (1H2021: 13.2%).

# E-commerce channels maintained strong momentum

E-commerce channels (including Retail Integrated and New Channel) maintained a strong development momentum and the sales during the period soared over 30.0% to RMB2710.405mn (1H2021: RMB2004.757mn), accounting for 24.2% of the overall sales (1H2021: 20.1%). In which, other new sales channels (including online-to-offline (O2O) platform, community group-buying, etc.), with sales accounting for more than 10.0% of the overall sales. The tissue paper sales in e-commerce channel increased by more than 30.0%, accounting for more than 21.0% of the sales of tissue paper. Hengan's strived to strengthen the development of e-commerce and maternity sales channels. The proportion of sales of disposable diapers through e-commerce and maternity channels increased to more than 50.0% and more than 20.0%, respectively. The turnover of overseas channel (including Wang-Zhang Group business) was RMB1072.226mn (1H2021: RMB883.319mn), accounting for 9.6% of the overall sales (1H2021: 8.9%).

# **Investment Thesis**

Since the overall operating environment was very challenging, and under the impact of lockdown and epidemic control measures, consumer sentiment in Mainland China became more cautious in the light of the epidemic. In addition, geopolitical upheavals affected the supply chain and exacerbated the rise in inflation, and given that the price of wood pulp is currently at a high level and the future trend is still uncertain, it is expected that the Hengan's gross profit margin will continue to be under pressure in 2H2O22. However, part of the related downside and earnings risk may have already priced-in. Rising raw material prices and operating costs have brought enormous pressure to the industry, which accelerated market consolidation of eliminating the weak and retaining the strong. Meanwhile, Hengan's multi-channel sales development has certain advantages, upgraded products and premium product series can offset some of the impact of the spike in raw material prices, and the national health awareness has further improved, that Hengan's business still considered defensible and resilience to buck the trend. We expect FY2022E-FY2023E EPS to be RMB2.82 and RMB3.33 respectively, with PT of HKD37.90, implies a FY2022E P/E of 12.3x (~5-yrs historical average and one standard deviation below). Our investment rating is "Accumulate".

# Risk factors

1) The price of raw materials continues to rise; 2) market competition intensifies; 3) channel development is not as expected; and 4) Sharp fluctuations in FX.





# **Financial**

| Dec Y/E, RMB mn               | FY19     | FY20     | FY21     | FY22E    | FY23    |
|-------------------------------|----------|----------|----------|----------|---------|
| Revenue                       | 22,493   | 22,374   | 20,790   | 22,913   | 23,747  |
| COGS                          | (13,804) | (12,918) | (13,018) | (14,821) | (14,980 |
| Gross Profit                  | 8,689    | 9,456    | 7,772    | 8,093    | 8,767   |
| Selling expenses              | (3,203)  | (3,469)  | (3,154)  | (3,624)  | (3,679  |
| General & Admin exp           | (1,285)  | (1,364)  | (1,373)  | (1,469)  | (1,513  |
| Others                        | 1,479    | 1,769    | 1,298    | 1,619    | 1,680   |
| Operating Profit              | 5,680    | 6,392    | 4,544    | 4,618    | 5,255   |
| Finance costs, net            | (633)    | (426)    | (171)    | (285)    | (191    |
| Share of result of a JV       | -        | (4)      | (43)     | (48)     | (49     |
| Profit before tax             | 5,047    | 5,961    | 4,330    | 4,286    | 5,015   |
| Income tax                    | (1,130)  | (1,353)  | (1,039)  | (987)    | (1,148  |
| Shareholders Net profit       | 3,908    | 4,595    | 3,274    | 3,286    | 3,849   |
| Reported EPS, Diluted         | 3.28     | 3.86     | 2.79     | 2.82     | 3.33    |
| DPS                           | 2.48     | 2.90     | 2.06     | 1.77     | 2.09    |
| Payout ratio                  | 76%      | 75%      | 74%      | 63%      | 63      |
| Shares outstanding            | 1,190    | 1,189    | 1,175    | 1,165    | 1,157   |
| Key Financial Data<br>Dec Y/E | FY19     | FY20     | FY21     | FY22E    | FY23    |
| Valuation Ratio               |          |          |          |          |         |
| P/S ratio, x                  | 1.6      | 1.5      | 1.5      | 1.5      | 1.5     |
| P/E ratio, x                  | 9.0      | 7.1      | 9.6      | 10.7     | 9.      |
| Dividend Yield, %             | 7.5%     | 8.8%     | 6.3%     | 5.9%     | 6.9     |
| Per share data (HKD)          |          |          |          |          |         |
| EPS                           | 3.67     | 4.61     | 3.41     | 3.08     | 3.63    |
| BVPS                          | 16.79    | 19.46    | 19.84    | 18.58    | 19.9    |
| DPS (HKD)                     | 2.48     | 2.90     | 2.06     | 1.93     | 2.28    |
| Growth & Margin               |          |          |          |          |         |
| Growth                        |          |          |          |          |         |
| Revenue Growth                | 9.6%     | -0.5%    | -7.1%    | 10.2%    | 3.6     |
| Gross Profit Growth           | 10.9%    | 8.8%     | -17.8%   | 4.1%     | 8.3     |
| Operating Profit Growth       | 4.6%     | 12.5%    | -28.9%   | 1.6%     | 13.8    |
| Net Profit Growth             | 2.9%     | 18.1%    | -27.4%   | -1.0%    | 17.0    |
| Margin                        |          |          |          |          |         |
| Gross Profit Margin           | 38.6%    | 42.3%    | 37.4%    | 35.3%    | 36.9    |
| Operating Profit Margin       | 25.3%    | 28.6%    | 21.9%    | 20.2%    | 22.1    |
| Net Profit Margin             | 17.4%    | 20.5%    | 15.7%    | 14.3%    | 16.2    |
| Key Ratios                    |          |          |          |          |         |
| ROE                           | 22.2%    | 24.3%    | 16.8%    | 16.7%    | 18.5    |
| ROA                           | 8.8%     | 10.5%    | 7.5%     | 7.7%     | 8.8     |

| Consolidated Statement of Financial | Position |        |        |        |        |
|-------------------------------------|----------|--------|--------|--------|--------|
| Dec Y/E, RMB mn                     | FY19     | FY20   | FY21   | FY22E  | FY23E  |
| Non Current Asset                   |          |        |        |        |        |
| PPE                                 | 7,822    | 7,571  | 7,297  | 7,339  | 7,437  |
| Others                              | 5,348    | 6,928  | 7,727  | 7,694  | 7,660  |
| Total Non Current Assets            | 13,170   | 14,499 | 15,024 | 15,033 | 15,097 |
| Current Asset                       |          |        |        |        |        |
| Inventory                           | 3,802    | 4,311  | 4,162  | 4,842  | 4,774  |
| Trade and other receivables         | 3,651    | 3,375  | 2,970  | 3,483  | 3,530  |
| Bank balance and cash               | 20,540   | 20,484 | 18,247 | 18,083 | 18,644 |
| Others                              | 2,074    | 1,772  | 1,890  | 1,903  | 1,914  |
| Total Current Assets                | 30,068   | 29,941 | 27,269 | 28,311 | 28,862 |
| Total Assets                        | 43,239   | 44,441 | 42,293 | 43,344 | 43,959 |
| Non Current Liabilities             |          |        |        |        |        |
| Long-term debt                      | 1,247    | 2,493  | 739    | 722    | 523    |
| Other Non-current Liabilities       | 176      | 225    | 235    | 221    | 205    |
| Total Non-current Liabilities       | 1,423    | 2,718  | 975    | 943    | 728    |
| Current Liabilities                 |          |        |        |        |        |
| Interest-bearing Borrowings         | 20,361   | 18,344 | 17,488 | 17,470 | 16,873 |
| Trade payables                      | 2,224    | 2,244  | 2,565  | 2,819  | 2,930  |
| Others                              | 1,079    | 1,474  | 1,984  | 2,004  | 1,964  |
| Total Current Liabilities           | 23,664   | 22,062 | 22,037 | 22,293 | 21,768 |
| Equity                              |          |        |        |        |        |
| Shareholders' equity                | 17,873   | 19,411 | 19,037 | 19,851 | 21,190 |
| Non-controlling interests           | 279      | 250    | 243    | 257    | 274    |
| Total equity                        | 18,152   | 19,661 | 19,280 | 20,108 | 21,464 |
| Total Liabilities and Equity        | 43,239   | 44,441 | 42,293 | 43,344 | 43,959 |

| Consolidated Statement of Cash Flow      |   |         |         |         |         |         |
|--|---|---------|---------|---------|---------|---------|
| Dec Y/E, RMB mn                          |   | FY19    | FY20    | FY21    | FY22E   | FY23E   |
| CFO                                      |   |         |         |         |         |         |
| Profit before income tax                 |   | 5,047   | 5,961   | 4,330   | 4,286   | 5,015   |
| D&A add-back                             | • | 816     | 837     | 871     | 761     | 750     |
| Others                                   |   | (1,353) | (1,918) | (1,378) | (1,445) | (1,763) |
| Net (inc)/dec working capital            | • | (1,094) | 161     | 781     | (940)   | 133     |
| Net cash flow from operating activities  |   | 3,416   | 5,042   | 4,604   | 2,663   | 4,135   |
| CFI                                      |   |         |         |         |         |         |
| Purchase of PP&E                         |   | (898)   | (761)   | (781)   | (771)   | (813)   |
| Others                                   |   | 2,012   | 2,317   | 3,457   | 2,103   | 2,567   |
| Net cash flow from investing activities  |   | 1,113   | 1,556   | 2,676   | 1,331   | 1,753   |
| CFF                                      |   |         |         |         |         |         |
| Dividends paid                           |   | (2,617) | (2,915) | (2,706) | (1,997) | (2,065) |
| Others                                   |   | (3,921) | (1,015) | (3,781) | (1,111) | (1,773) |
| Net cash flows from financing activities |   | (6,539) | (3,929) | (6,487) | (3,108) | (3,838) |
| Net Change in Cash                       |   | (2,009) | 2,668   | 793     | 886     | 2,050   |
| Cash and CE at Y/E                       |   | 9,120   | 11,607  | 12,340  | 13,226  | 15,276  |

Current Price as of: November 10

Source: PSHK Est.



#### PHILLIP RESEARCH STOCK SELECTION SYSTEMS

| Total Return | Recommendation | Rating | Remarks                                     |
|--------------|----------------|--------|---|
| >+20%        | Buy            | 1      | >20% upside from the current price          |
| +5% to +20%  | Accumulate     | 2      | +5% to +20%upside from the current price    |
| -5% to +5%   | Neutral        | 3      | Trade within ±5% from the current price     |
| -5% to -20%  | Reduce         | 4      | -5% to -20% downside from the current price |
| <-20%        | Sell           | 5      | >20%downside from the current price         |

We do not base our recommendations entirely on the above quantitative return bands. We consider qualitative factors like (but not limited to) a stock's risk reward profile, market sentiment, recent rate of share price appreciation, presence or absence of stock price catalysts, and speculative undertones surrounding the stock, before making our final recommendation

# **GENERAL DISCLAIMER**

This publication is prepared by Phillip Securities (Hong Kong) Ltd ("Phillip Securities"). By receiving or reading this publication, you agree to be bound by the terms and limitations set out below.

This publication shall not be reproduced in whole or in part, distributed or published by you for any purpose. Phillip Securities shall not be liable for any direct or consequential loss arising from any use of material contained in this publication.

The information contained in this publication has been obtained from public sources which Phillip Securities has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the "Research") contained in this publication are based on such information and are expressions of belief only. Phillip Securities has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in this publication is subject to change, and Phillip Securities shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will Phillip Securities be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages.

Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this material are as of the date indicated and are subject to change at any time without prior notice.

This material is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this material may not be suitable for all investors and a person receiving or reading this material should seek advice from a financial adviser regarding the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.

This publication should not be relied upon as authoritative without further being subject to the recipient's own independent verification and exercise of judgment. The fact that this publication has been made available constitutes neither a recommendation to enter into a particular transaction nor a representation that any product described in this material is suitable or appropriate for the recipient. Recipients should be aware that many of the products which may be described in this publication involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.

Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in this research should take into account existing public information, including any registered prospectus in respect of such security.

# **Disclosure of Interest**

Analyst Disclosure: Neither the analyst(s) preparing this report nor his associate has any financial interest in or serves as an officer of the listed corporation covered in this report

Firm's Disclosure: Phillip Securities does not have any investment banking relationship with the listed corporation covered in this report nor any financial interest of 1% or more of the market capitalization in the listed corporation. In addition, no executive staff of Phillip Securities serves as an officer of the listed corporation.

# **Availability**

The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited ("PSHK") believed to be accurate. PSHK does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. PSHK (or its affiliates or employees) may have positions in relevant investment products. For details of different product's risks, please visit the Risk Disclosures Statement on http://www.phillip.com.hk.

© 2022 Phillip Securities (Hong Kong) Limited





#### **Contact Information (Regional Member Companies)**

#### SINGAPORE

# Phillip Securities Pte Ltd

250 North Bridge Road, #06-00 Raffles City Tower, Singapore 179101 Tel: (65) 6533 6001 Fax: (65) 6535 3834

# www.phillip.com.sg

# INDONESIA

# **PT Phillip Securities Indonesia**

ANZ Tower Level 23B, Jl Jend Sudirman Kav 33A, Jakarta 10220, Indonesia

Tel (62) 21 5790 0800 Fax: (62) 21 5790 0809 www.phillip.co.id

# THAILAND

# Phillip Securities (Thailand) Public Co. Ltd.

15th Floor, Vorawat Building, 849 Silom Road, Silom, Bangrak, Bangkok 10500 Thailand Tel (66) 2 2268 0999 Fax: (66) 2 2268 0921 www.phillip.co.th

# **UNITED STATES**

#### Phillip Futures Inc.

141 W Jackson Blvd Ste 3050
The Chicago Board of Trade Building
Chicago, IL 60604 USA
Tel (1) 312 356 9000 Fax: (1) 312 356 9005

#### MALAYSIA

# Phillip Capital Management Sdn Bhd

B-3-6 Block B Level 3, Megan Avenue II, No. 12, Jalan Yap Kwan Seng, 50450 Kuala Lumpur Tel (60) 3 2162 8841 Fax (60) 3 2166 5099 www.poems.com.my

#### CHINA

# Phillip Financial Advisory (Shanghai) Co. Ltd.

No 436 Heng Feng Road, Green Tech Tower Unit 604 Shanghai 200 070

Tel (86) 21 5169 9400 Fax: (86) 21 6091 1155 www.phillip.com.cn

# FRANCE

#### King & Shaxson Capital Ltd.

3rd Floor, 35 Rue de la Bienfaisance 75008 Paris France Tel (33) 1 4563 3100 Fax : (33) 1 4563 6017

# $\underline{www.kingandshaxson.com}$

# AUSTRALIA PhillipCapital Australia

L Level 10, 330 Collins Street Melbourne VIC 3000 Australia Tel: (61) 3 9618 8238 Fax: (61) 3 9200 2277

www.phillipcapital.com.au

#### HONG KONG

# Phillip Securities (HK) Ltd

11/F United Centre 95 Queensway Hong Kong Tel (852) 2277 6600 Fax: (852) 2868 5307 www.phillip.com.hk

#### JAPAN

# Phillip Securities Japan, Ltd

4-2 Nihonbashi Kabutocho, Chuo-ku Tokyo 103-0026 Tel: (81) 3 3666 2101 Fax: (81) 3 3664 0141

www.phillip.co.jp

#### INDIA

# PhillipCapital (India) Private Limited

No. 1, 18th Floor, Urmi Estate, 95 Ganpatrao Kadam Marg, Lower Parel West, Mumbai 400013 Tel: (9122) 2300 2999 Fax: (9122) 6667 9955 www.phillipcapital.in

# UNITED KINGDOM

# King & Shaxson Ltd.

6th Floor, Candlewick House, 120 Cannon Street London, EC4N 6AS Tel (44) 20 7929 5300 Fax: (44) 20 7283 6835 www.kingandshaxson.com

#### SRI LANKA

# Asha Phillip Securities Limited

Level 4, Millennium House, 46/58 Navam Mawatha, Colombo 2, Sri Lanka Tel: (94) 11 2429 100 Fax: (94) 11 2429 199 www.ashaphillip.net/home.htm